Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substituted hydroxyethylamines

一种取代基、烷基的技术，应用在胺化合物的前体药物领域，能够解决没有中止、预防或逆转阿尔茨海默氏症深化的有效治疗方法等问题

Inactive Publication Date: 2007-12-19
ELAN PHARM INC +1
View PDF31 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Currently, there are no effective treatments to halt, prevent or reverse the progression of Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted hydroxyethylamines
  • Substituted hydroxyethylamines
  • Substituted hydroxyethylamines

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0782]Panel A illustrates a general method for preparing compound (Y) used in the present invention. The anti-Alzheimer's compound (Y) of the present invention is prepared using the corresponding amino acid (I) as a raw material. The amino acid (I) is known to those skilled in the art, or can be easily prepared from known compounds by methods known to those skilled in the art. Compound (Y) of the present invention has at least two enantiocenters, which give rise to four enantiomers. The first of these enantiocenters is derived from the starting amino acid (I). It is preferred to obtain or prepare the desired enantiomer (S) commercially rather than to produce an enantiomerically non-unitary mixture and then have to isolate the desired enantiomer (S). The method preferably uses (S)-amino acid (I) having a single enantiostructural structure and the same configuration as the product compound (Y) as a starting material.

[0783] More preferably, R 1 Yes-(CH 2 ) 0-1 -(R 1-芳基 ...

Embodiment 1

[1064] Example 1(1S)-3-bromo(3,5-difluorobenzyl)-2-oxopropylcarbamate tert-butyl ester (III)

[1065] N-Methyl-morpholine (5.83 mL, 53 mmol, 1.05 eq.) was added to (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3 , 5-difluorophenyl)propionic acid (II, 15 g, 50 mmol), and the reaction was cooled to -78°C. Isobutyl chloroformate (6.87 mL, 53 mmol, 1.05 eq.) was added rapidly. The cooling bath was then removed and the mixture was stirred for 1 hour. The reaction was monitored by TLC to ensure completion, then the mixture was filtered and washed with anhydrous THF (50 mL) and kept cold at -20°C in the filter flask.

[1066] A 500-mL graduated cylinder containing diethyl ether (200 mL) and aqueous potassium hydroxide (40%, 60 mL) was placed in an ice-salt bath. 1-Methyl-3-nitro-1-nitrosoguanidine (5.6 g, 106 mmol, 2.1 eq.) was added slowly while stirring, keeping the temperature below 0°C. The mixture turned yellow and continued to foam for 10 minutes. Stirring was stopped, the layers...

Embodiment 2

[1067] Example 2 (1S, 2S)-3-bromo-1-(3,5-difluorobenzyl)-2-hydroxypropylcarbamate tert-butyl ester (IV)

[1068] Add sodium borohydride (1.32 g, 34.9 mmol, 1.1 eq.) to (1 S)-3-bromo(3,5-difluorobenzyl)- In tert-butyl 2-oxopropylcarbamate (III, Example 1, 12 g, 31.75 mmol). The reaction mixture was stirred for 0.5 h and passed by TLC (ethyl acetate / hexane, 20 / 80; Rf = 0.2). The mixture was quenched with water (10 mL), and the solvent was removed by heating under reduced pressure (not exceeding 30° C.) to dryness. The solid was partitioned between dichloromethane and water, washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to obtain the title compound, TLC (ethyl acetate / hexane, 20 / 80) R f =0.2; MS(MH + ) = 381.2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses the compound of chemical formula (I), wherein variable R 1 , R 2 , R 3 , R 4 , R N , R C is defined as described herein. These compounds have activity as beta-secretase inhibitors and are therefore useful in the treatment of various diseases such as Alzheimer's disease.

Description

[0001] Cross References to Related Applications [0002] This application claims priority from US Provisional Application No. 60 / 359,953, filed February 27, 2002, the disclosure of which is incorporated herein by reference in its entirety. Background technique [0003] 1. Field of invention [0004] The present invention relates to prodrugs of a class of amine compounds useful in the treatment of Alzheimer's disease and similar diseases. [0005] 2. Description of related technologies [0006] Alzheimer's disease (AD) is a progressive degenerative disease of the brain mainly associated with aging. The clinical manifestations of AD are characterized by loss of memory, cognition, reasoning, judgment, and orientation. As the disease progresses, motor, sensory, and language abilities are also affected, until there is generalized impairment of multiple cognitive functions. These cognitive losses develop gradually, but usually lead to severe impairment and eventual death with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C233/78C07D295/20C07D307/20A61K31/166A61K31/132A61K31/33A61P25/28C07C271/16C07C271/20C07C217/58C07C247/10C07C247/12C07C255/27C07C311/16C07D295/22C07D295/12A61K31/137A61K31/165A61K31/195A61K31/215A61K31/325A61K31/341A61K31/36A61K31/381A61K31/40A61K31/4045A61K31/41A61K31/415A61K31/417A61K31/42A61K31/421A61K31/423A61K31/4245A61K31/426A61K31/429A61K31/433A61K31/44A61K31/4402A61K31/4406A61K31/4409A61K31/455A61K31/495A61K31/4965A61K31/50A61K31/505A61K31/5375A61K47/48A61P25/16C07C255/57C07D207/09C07D207/335C07D207/48C07D209/14C07D211/58C07D213/36C07D213/71C07D213/81C07D213/82C07D213/89C07D231/12C07D231/16C07D233/64C07D233/84C07D237/08C07D239/26C07D241/12C07D257/04C07D261/10C07D261/18C07D263/32C07D263/46C07D263/48C07D263/58C07D271/06C07D271/10C07D277/20C07D277/28C07D277/36C07D285/08C07D285/12C07D295/205C07D295/26C07D307/14C07D307/52C07D307/64C07D317/58C07D333/20C07D333/28C07D333/34C07D333/38C07D333/40C07D513/04
CPCC07C2102/10C07C271/20C07D317/68C07D303/36C07D295/26C07D209/08C07C271/16C07C233/78C07C217/58C07C247/10C07D307/20C07D295/205C07C247/12A61K47/48138C07D231/26C07D417/12C07C2101/14C07C255/57C07C2103/18C07D249/18C07D213/82C07C2601/14C07C2602/10C07C2603/18A61K47/556A61P25/16A61P25/28A61K31/132
Inventor J·维格河斯B·贾戈德津斯卡M·梅拉德J·P·贝克R·E·泰布林克D·格季曼
Owner ELAN PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com